Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999

Gynecologic Oncology

Volumn 93, Issue 1, 2004, Pages 204-208

  Brooks, Sandra E ^a   Zhan, Min ^a   Cote, Timothy ^b   Baquet, Claudia R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Race; Survival; Uterine sarcoma

Indexed keywords

ADENOSARCOMA; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIUM SARCOMA; EUROPEAN AMERICAN; FEMALE; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL ANALYSIS; SURVIVAL TIME; UTERUS; UTERUS SARCOMA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; CARCINOSARCOMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; SARCOMA, ENDOMETRIAL STROMAL; SEER PROGRAM; UTERINE NEOPLASMS;

EID: 1842425382     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.12.029     Document Type: Article

References (17)

1. Young J.et al. Surveillance, epidemiology and end results program: incidence and mortality data 1973-1977. Natl. Cancer Inst. Mongr. vol. 57:1981;1-1082.
2. Nordal R., Thoresen S. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur. J. Cancer. 33:1997;907-911.
3. Harlow B., Weiss N., Lofton S. The epidemiology of sarcomas of the uterus. JNCI. 76:1986;399-402.
4. Platz C., Benda J. Female genital tract cancer. Cancer. 75:1995;270-294.
5. AJCC cancer staging manual. fifth ed. 1997;Lippincott Williams and Wilkins, Philadelphia.
6. SEER summary staging manual. 2003.
7. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1998). National Cancer Institute, DCCPS, Surveillance Research Program. Bethesda, MD: Cancer Statistics Branch; 2001.
8. Ederer F., Axtell L., Cutler T. Relative survival rate: a statistical methodology. J. Natl. Cancer Inst. Monographs. 6:1961;101-121.
9. Schwartz S.M.et al. Exogenous sex hormone use, correlates of endogenous hormone levels and the incidence of histologic types of sarcoma of the uterus. Cancer. 77:1996;717-724.
10. Wysowski D.et al. Uterine sarcoma associated with Tamoxifen use. N. Engl. J. Med. 346:2002;1832-1833.
11. Wickerham D.et al. Association of Tamoxifen and uterine sarcoma. J. Clin. Oncol. 20:2002;2758-2760.
12. Hicks M.et al. The National Cancer Database Report on endometrial carcinoma in African American women. Cancer. 83:1998;2629-2637.
13. Brooks S.et al. Health care cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma. Cancer. 92(4):2001;950-958.
14. Katz S., Hofer T. Socioeconomic disparities in preventive care persist despite universal coverage. JAMA. 272:1994;530-534.
15. O'Malley C.et al. Socioeconomic status and breast carcinoma survival in four racial/ethnic groups. Cancer. 97:2003;1303-1311.
16. Cross C.K., Harris J., Recht R.A. Race, socioecnomic status, and breast carcinoma in the U.S. Cancer. 95:2002;1989-1999.
17. Echt G.et al. Treatment of uterine sarcomas. Cancer. 66:1990;35-39.